Status:
TERMINATED
PHA-739358 for the Treatment of Multiple Myeloma
Lead Sponsor:
Nerviano Medical Sciences
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of tr...
Eligibility Criteria
Inclusion
- active multiple myeloma progressing after at least 2 prior lines of treatment
- measurable disease
- t(4;14) translocation
- life expectancy of at least 3 months
Exclusion
- uncontrolled hypertension
- myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the past 6 months.
- pregnancy or breast feeding
- active infections, including HIV
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00872300
Start Date
October 1 2008
End Date
September 1 2010
Last Update
May 28 2014
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
MAYO Clinic
Scottsdale, Arizona, United States, 85259
2
The Robert H Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States, 60611
3
Hôpital Huriez, Centre Hospitalier Régional Universitaire de Lille
Lille, France, 59037
4
University Hospital Hôtel-Dieu
Nantes, France, 44093